{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:04:16Z","timestamp":1782284656156,"version":"3.54.5"},"reference-count":30,"publisher":"Codon Publications","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.aller.2020.05.008","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:28:20Z","timestamp":1595316500000},"page":"738-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement"],"prefix":"10.15586","volume":"48","author":[{"given":"I.B.P.","family":"Ibis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Erdur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Karaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gulez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Genel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","reference":[{"key":"10.1016\/j.aller.2020.05.008_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of intravenous immunoglobulin in immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aller.2020.05.008_bib0010","first-page":"461","article-title":"New uses of intravenous immunoglobulin therapy","volume":"154","author":"Wilson","year":"1991","journal-title":"West J Med."},{"key":"10.1016\/j.aller.2020.05.008_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/j.1875-9114.1987.tb03512.x","article-title":"Methodology and safety considerations in the produciton of an intravenous immunoglobulin preparation","volume":"7","author":"Friedli","year":"1987","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.aller.2020.05.008_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1034\/j.1398-9995.2003.00239.x","article-title":"IVIG-mechanism of action","volume":"58","author":"Simon","year":"2003","journal-title":"Allergy."},{"key":"10.1016\/j.aller.2020.05.008_bib0025","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"9","author":"Roifman","year":"1987","journal-title":"Lancet."},{"key":"10.1016\/j.aller.2020.05.008_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0002-9343(84)90320-6","article-title":"Intravenous immunoglobulin therapy in hypogammaglobulinemia. A review","volume":"30","author":"Pirofsky","year":"1984","journal-title":"Am J Med."},{"key":"10.1016\/j.aller.2020.05.008_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1871530316666160724214418","article-title":"The use of immunoglobulin therapy in primary immunodeficiency diseases","volume":"16","author":"Azizi","year":"2016","journal-title":"Endocr Metab Immune Disord Drug Targets."},{"issue":"1","key":"10.1016\/j.aller.2020.05.008_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/17512433.2016.1105131","article-title":"Managing patients with side effects and adverse events to immunoglobulin therapy","volume":"9","author":"Azizi","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.aller.2020.05.008_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev."},{"key":"10.1016\/j.aller.2020.05.008_bib0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Richard Stiehm","year":"2013","journal-title":"Transf Med Rev."},{"key":"10.1016\/j.aller.2020.05.008_bib0055","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneurol.2010.223","article-title":"Safety and tolerability of immunoglobulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Donofrio","year":"2010","journal-title":"Arch Neurol."},{"key":"10.1016\/j.aller.2020.05.008_bib0060","first-page":"420","article-title":"Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations","volume":"43","author":"Struff","year":"2005","journal-title":"Int J Clin Pharmacol Toxicol."},{"key":"10.1016\/j.aller.2020.05.008_bib0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Shroeder","year":"2012","journal-title":"Infection."},{"key":"10.1016\/j.aller.2020.05.008_bib0070","first-page":"247","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.aller.2020.05.008_bib0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Childhood."},{"key":"10.1016\/j.aller.2020.05.008_bib0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.aller.2020.05.008_bib0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000467578","article-title":"Intravenous gamma-globulin infusions in patients with hypo-gamma-globulinemia: prevention of adverse reactions with corticosteroids","volume":"34","author":"Gislason","year":"1978","journal-title":"Vox Sang."},{"key":"10.1016\/j.aller.2020.05.008_bib0090","first-page":"518","article-title":"Renal insufficiency and failure associated with immunoglobulin intravenous therapy-United States, 1995-1998","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR."},{"key":"10.1016\/j.aller.2020.05.008_bib0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1399-3038.1994.tb00230.x","article-title":"\u0130ntravenous immunoglobulin, pharmacology, clinical uses and mechanism of action","volume":"5","author":"Schiff","year":"1994","journal-title":"Pediatr Allergy Immunol."},{"key":"10.1016\/j.aller.2020.05.008_bib0100","first-page":"175","article-title":"Neutropenia in a patient receiving intravenous immunoglobulin","volume":"64","author":"Tam","year":"1996","journal-title":"J Neurol Immunol."},{"key":"10.1016\/j.aller.2020.05.008_bib0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0002-9343(87)90112-4","article-title":"Hemolytic anemia following intravenous gammaglobulin administration","volume":"82","author":"Brox","year":"1987","journal-title":"Am J Med."},{"key":"10.1016\/j.aller.2020.05.008_bib0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/jaut.1999.0302","article-title":"In vivo administration of intravenous immunoglobulin can lead to enhanced erythrocytese questration","volume":"13","author":"Kessary-Shoham","year":"1999","journal-title":"J Autoimmun."},{"key":"10.1016\/j.aller.2020.05.008_bib0115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","article-title":"Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases","volume":"20","author":"Koffman","year":"1997","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.aller.2020.05.008_bib0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4065\/75.1.83","article-title":"Deep venosus thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin related thrombotic complications","volume":"75","author":"Go","year":"2000","journal-title":"Mayo Clinic Proc."},{"key":"10.1016\/j.aller.2020.05.008_bib0125","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.aller.2020.05.008_bib0130","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience","volume":"49","author":"Kaba","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"10.1016\/j.aller.2020.05.008_bib0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy."},{"issue":"Suppl 2","key":"10.1016\/j.aller.2020.05.008_bib0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/trf.13158","article-title":"Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?","volume":"55","author":"Zimring","year":"2015","journal-title":"Transfusion."},{"key":"10.1016\/j.aller.2020.05.008_bib0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","article-title":"Increased risk of adverse events when changing intravenous immunoglobulin preparations","volume":"136","author":"Ameratunga","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.aller.2020.05.008_bib0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","article-title":"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency","volume":"32","author":"Wasserman","year":"2012","journal-title":"J Clin Immunol."}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620301154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620301154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T22:52:39Z","timestamp":1609455159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301054620301154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0301054620301154"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2020.05.008","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement","name":"articletitle","label":"Article Title"},{"value":"Allergologia et Immunopathologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aller.2020.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEICAP. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}